SOLARAPP Stock Overview
Manufactures, produces, processes, formulates, sells, imports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Solara Active Pharma Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹258.70 |
| 52 Week High | ₹258.70 |
| 52 Week Low | ₹200.00 |
| Beta | 0.99 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 20.97% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| SOLARAPP | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | n/a | 1.2% | 1.7% |
| 1Y | n/a | 48.8% | 44.8% |
Return vs Industry: Insufficient data to determine how SOLARAPP performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SOLARAPP performed against the Indian Market.
Price Volatility
| SOLARAPP volatility | |
|---|---|
| SOLARAPP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: SOLARAPP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SOLARAPP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 2,361 | Poorvank Purohit | www.solara.co.in |
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The company offers APIs for anesthetics, anthelmintic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antifungal, antigout agent, antihistamine, antihyperlipoproteinemic, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcerative, anxiolytic, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, chronic kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, loop diuretic, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, topical anti-infectives, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, nucleoside inhibitor, aprepitant, NSAIDs, and type-II diabetes therapeutic categories. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support.
Solara Active Pharma Sciences Limited Fundamentals Summary
| SOLARAPP fundamental statistics | |
|---|---|
| Market cap | ₹27.72b |
| Earnings (TTM) | -₹5.67b |
| Revenue (TTM) | ₹12.89b |
2.2x
P/S Ratio-4.9x
P/E RatioIs SOLARAPP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOLARAPP income statement (TTM) | |
|---|---|
| Revenue | ₹12.89b |
| Cost of Revenue | ₹8.05b |
| Gross Profit | ₹4.84b |
| Other Expenses | ₹10.51b |
| Earnings | -₹5.67b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -118.20 |
| Gross Margin | 37.54% |
| Net Profit Margin | -44.02% |
| Debt/Equity Ratio | 106.7% |
How did SOLARAPP perform over the long term?
See historical performance and comparison